

Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 402618-00022 8.0 2024/09/28 Date of first issue: 2015/12/11

1. PRODUCT AND COMPANY IDENTIFICATION

Chemical product name Ribavirin Solid Formulation

Supplier's company name, address and phone number

Company name of supplier MSD

Address Kumagaya, Saitama Prefecture, Xicheng 810 MSD Co., Ltd.

Menuma factory

Telephone 048-588-8411

E-mail address EHSDATASTEWARD@msd.com

Emergency telephone number : +1-908-423-6000

Recommended use of the chemical and restrictions on use

Recommended use Pharmaceutical Restrictions on use Not applicable

2. HAZARDS IDENTIFICATION

GHS classification of chemical product

Germ cell mutagenicity Category 2

Reproductive toxicity Category 1B

Specific target organ toxicity - :

single exposure

Category 3

Specific target organ toxicity - : Category 1 (Blood)

repeated exposure (Oral)

GHS label elements

Hazard pictograms

Signal word Danger

Hazard statements H335 May cause respiratory irritation.

H341 Suspected of causing genetic defects.

H360Df May damage the unborn child. Suspected of damaging

H372 Causes damage to organs (Blood) through prolonged or



MSD A Public

Ribavirin Solid Formulation

Version 8.0

Revision Date: 2024/09/28

SDS Number: 402618-00022

Date of last issue: 2024/04/06 Date of first issue: 2015/12/11

repeated exposure if swallowed.

Precautionary statements

Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read and understood.

P260 Do not breathe dust.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product. P271 Use only outdoors or in a well-ventilated area.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/doctor if you feel unwell.

P308 + P313 IF exposed or concerned: Get medical advice/attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Important symptoms and outlines of the emergency assumed

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)	ENCS No.
Ribavirin	36791-04-5	>= 60 - < 70	9-1515
Cellulose	9004-34-6	>= 10 - < 20	
Magnesium stearate	557-04-0	>= 1 - < 10	2-611

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 402618-00022 Date of first issue: 2015/12/11

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention.
Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

May cause respiratory irritation.

Most important symptoms and effects, both acute and

delayed

Suspected of causing genetic defects.

May damage the unborn child. Suspected of damaging fertili-

ty.

Causes damage to organs through prolonged or repeated

exposure if swallowed.

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation. First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Protection of first-aiders

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire-

fighting

Avoid generating dust; fine dust dispersed in air in sufficient

concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides Metal oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment.

Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.





Version SDS Number: Date of last issue: 2024/04/06 Revision Date: 8.0 2024/09/28 402618-00022 Date of first issue: 2015/12/11

for firefighters

Special protective equipment : In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- : tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions Avoid release to the environment.

> Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up Surround spill with absorbents and place a damp covering over the area to minimise entry of the material into the air. Add excess liquid to allow the material to enter into solution.

Soak up with inert absorbent material.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

7. HANDLING AND STORAGE

Handling

Technical measures Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Do not get on skin or clothing. Advice on safe handling

Do not breathe dust. Do not swallow.

Avoid contact with eves.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 402618-00022 Date of first issue: 2015/12/11

practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Already sensitised individuals, and those susceptible

to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respira-

tory irritants or sensitisers.

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.
Oxidizing agents

Avoidance of contact

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

Storage

Conditions for safe storage : Keep in properly labelled containers.

Store locked up. Keep tightly closed.

Keep in a cool, well-ventilated place.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Packaging material : Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Threshold limit value and permissible exposure limits for each component in the work environment

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Concentration standard / Permissible concentration	Basis
Ribavirin	36791-04-5	Wipe limit	400 μg/100 cm ²	Internal
		TWA	40 μg/m3 (OEB 3)	Internal
Cellulose	9004-34-6	TWA	10 mg/m3	ACGIH
Magnesium stearate	557-04-0	TWA (Inhal- able particu- late matter)	10 mg/m3	ACGIH



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 402618-00022 Date of first issue: 2015/12/11

TWA (Res- 3 mg/m3 ACGIH pirable par- ticulate mat- ter)

Engineering measures : All engineering controls should be implemented by facility

design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face con-

tainment devices).
Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type Hand protection Particulates type

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

posable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state : powder

Colour : white

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Boiling point, initial boiling point and boiling range

No data available



Ribavirin Solid Formulation

Version SDS Number: Date of last issue: 2024/04/06 **Revision Date:** 8.0 2024/09/28 402618-00022 Date of first issue: 2015/12/11

Flammability (solid, gas) May form explosive dust-air mixture during processing, han-

dling or other means.

Flammability (liquids) No data available

Lower explosion limit and upper explosion limit / flammability limit

Upper explosion limit / Up- : No data available

per flammability limit

Lower explosion limit / Lower flammability limit No data available

Flash point No data available

Decomposition temperature No data available

No data available рΗ

Evaporation rate Not applicable

Auto-ignition temperature No data available

Viscosity

Viscosity, kinematic Not applicable

Solubility(ies)

Water solubility No data available

Partition coefficient: n-

octanol/water

Not applicable

Not applicable Vapour pressure

Density and / or relative density

Relative density No data available

Density No data available

Relative vapour density Not applicable

Explosive properties Not explosive

Oxidizing properties The substance or mixture is not classified as oxidizing.

Particle characteristics

Particle size No data available

10. STABILITY AND REACTIVITY

Reactivity Not classified as a reactivity hazard.



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 402618-00022 Date of first issue: 2015/12/11

Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.
Oxidizing agents

Incompatible materials

Hazardous decomposition

products

No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of:

exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg

Method: Calculation method

Components:

Ribavirin:

Acute oral toxicity : LD50 (Rat): 4,116 - 5,584 mg/kg

LD50 (Mouse): > 10,000 mg/kg

LD50 (Dog): >= 1,500 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of :

administration)

LD50 (Rat): 1,554 - 1,758 mg/kg

Application Route: Intraperitoneal

LD50 (Mouse): 1,268 mg/kg Application Route: Intraperitoneal

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 402618-00022 Date of first issue: 2015/12/11

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 423

Assessment: The substance or mixture has no acute oral tox-

icity

Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Components:

Ribavirin:

Remarks : No data available

May irritate skin.

Magnesium stearate:

Species : Rabbit

Result : No skin irritation

Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Ribavirin:

Remarks : No data available

May irritate eyes.

Magnesium stearate:

Species : Rabbit

Result : No eye irritation

Remarks : Based on data from similar materials

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 402618-00022 Date of first issue: 2015/12/11

Components:

Ribavirin:

Remarks : No data available

Magnesium stearate:

Test Type : Maximisation Test Exposure routes : Skin contact Species : Guinea pig

Method : OECD Test Guideline 406

Result : negative

Remarks : Based on data from similar materials

Germ cell mutagenicity

Suspected of causing genetic defects.

Components:

Ribavirin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: Rodent cell line

Result: positive

Test Type: Chromosomal aberration Test system: Human lymphocytes

Result: negative

Genotoxicity in vivo : Test Type: dominant lethal test

Species: Rat Result: negative

Test Type: Mouse Lymphoma

Species: Mouse Result: positive

Test Type: Micronucleus test

Species: Mouse Result: positive

Germ cell mutagenicity -

Assessment

Positive result(s) from in vivo mammalian somatic cell muta-

genicity tests.

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 402618-00022 Date of first issue: 2015/12/11

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion

Result: negative

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Result: negative

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:

Ribavirin:

Species : Mouse
Application Route : Oral
Exposure time : 6 Months

LOAEL : 75 mg/kg body weight

Result : negative Target Organs : Blood, Testes

Remarks : The mechanism or mode of action may not be relevant in

humans.

Species : Rat
Application Route : Oral
Exposure time : 2 Years

NOAEL : 10 mg/kg body weight

Result : negative

Remarks : The mechanism or mode of action may not be relevant in

humans.

Species: MouseApplication Route: OralExposure time: 18 MonthsResult: negative

Remarks : The mechanism or mode of action may not be relevant in

humans.



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 402618-00022 Date of first issue: 2015/12/11

Cellulose:

Species: RatApplication Route: IngestionExposure time: 72 weeksResult: negative

Reproductive toxicity

May damage the unborn child. Suspected of damaging fertility.

Components:

Ribavirin:

Effects on fertility : Test Type: Fertility

Species: Rat, male

Application Route: Intraperitoneal injection Fertility: LOAEL: < 20 mg/kg body weight

Symptoms: Reduced fertility

Result: positive

Test Type: Fertility Species: Mouse, male Application Route: Oral

Fertility: LOAEL: 35 mg/kg body weight

Symptoms: Reduced fertility

Result: positive

Test Type: Fertility Species: Rat, females Application Route: Oral

Fertility: NOAEL: 10 mg/kg body weight

Result: Animal testing did not show any effects on fertility.

Test Type: Fertility Species: Rat, male Application Route: Oral

Fertility: NOAEL: 160 mg/kg body weight

Result: Animal testing did not show any effects on fertility.

Effects on foetal develop-

ment

Test Type: Development Species: Rat, female

Application Route: Oral

Developmental Toxicity: LOAEL: <= 1 mg/kg body weight Symptoms: Reduced body weight, Reduced number of viable

fetuses, Skeletal malformations

Result: Embryotoxic effects and adverse effects on the off-

spring were detected.

Test Type: Development Species: Rabbit, female Application Route: Oral

General Toxicity Maternal: LOAEL: 1 mg/kg body weight Developmental Toxicity: LOAEL: 1 mg/kg body weight



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 402618-00022 Date of first issue: 2015/12/11

Symptoms: Reduced body weight, Skeletal malformations Result: Embryotoxic effects and adverse effects on the off-

spring were detected.

Test Type: Development Species: Hamster Application Route: Oral

Developmental Toxicity: LOAEL: 2.5 mg/kg body weight Symptoms: Skeletal and visceral variations, Total Resorptions

/ resorption rate

Result: Embryotoxic effects and adverse effects on the off-

spring were detected.

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

General Toxicity Maternal: NOAEL: 0.3 mg/kg body weight Embryo-foetal toxicity: LOAEL: 1 mg/kg body weight

Symptoms: Skeletal malformations

Result: positive

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on foetal develop-

ment

Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

Result: negative

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the

reproduction/developmental toxicity screening test

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 422

Result: negative

Remarks: Based on data from similar materials

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Ingestion

Result: negative

Remarks: Based on data from similar materials



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 402618-00022 Date of first issue: 2015/12/11

STOT - single exposure

May cause respiratory irritation.

Components:

Ribavirin:

Assessment : May cause respiratory irritation.

STOT - repeated exposure

Causes damage to organs (Blood) through prolonged or repeated exposure if swallowed.

Components:

Ribavirin:

Exposure routes : Ingestion Target Organs : Blood

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Ribavirin:

Species : Monkey LOAEL : 30 mg/kg Exposure time : 10 d

Target Organs : Blood, Gastrointestinal tract

Species: RatNOAEL: 7.6 mg/kgApplication Route: InhalationExposure time: 90 d

Target Organs : Blood, Lungs

Species : Dog
NOAEL : 5 mg/kg
Application Route : Oral
Exposure time : 1 yr

Target Organs : Blood, Gastrointestinal tract

Species : Mouse

NOAEL : 20 mg/kg

Application Route : Oral

Exposure time : 18 Months

Target Organs : Blood, Cardio-vascular system

Cellulose:

Species : Rat

NOAEL : >= 9,000 mg/kg
Application Route : Ingestion



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 402618-00022 Date of first issue: 2015/12/11

Exposure time : 90 Days

Magnesium stearate:

Species : Rat

NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Remarks : Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Ribavirin:

Inhalation : Symptoms: Headache, Dizziness

Remarks: Based on Human Evidence

Skin contact : Remarks: May cause eye irritation.

Based on Human Evidence

Eye contact : Remarks: May cause eye irritation.

Based on Human Evidence

Ingestion : Symptoms: blood effects, immune system effects, anorexia,

Dizziness, insomnia, Fatigue, Headache, Itching, Rash, liver

function change, Gastrointestinal disturbance

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Ribavirin:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 119 mg/l

Exposure time: 96 h

Toxicity to daphnia and other:

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 117 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 119

mg/l

Exposure time: 96 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 6.9



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 402618-00022 Date of first issue: 2015/12/11

mg/l

Exposure time: 96 h

Method: OECD Test Guideline 201

Toxicity to microorganisms : EC50: > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l

Exposure time: 48 h

Remarks: Based on data from similar materials

Magnesium stearate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l

Exposure time: 48 h Method: DIN 38412

Remarks: Based on data from similar materials

Toxicity to daphnia and other:

aquatic invertebrates

EL50 (Daphnia magna (Water flea)): > 1 mg/l

Exposure time: 47 h

Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials

No toxicity at the limit of solubility

Toxicity to algae/aquatic

plants

EL50 (Pseudokirchneriella subcapitata (green algae)): > 1

mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

No toxicity at the limit of solubility

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1

mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l

Exposure time: 16 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 402618-00022 Date of first issue: 2015/12/11

Persistence and degradability

Components:

Cellulose:

Biodegradability : Result: Readily biodegradable.

Magnesium stearate:

Biodegradability : Result: Not biodegradable

Remarks: Based on data from similar materials

Bioaccumulative potential

Components:

Ribavirin:

Partition coefficient: n- :

octanol/water

log Pow: 0.971

Magnesium stearate:

Partition coefficient: n-

octanol/water

log Pow: > 4

Mobility in soil

No data available

Hazardous to the ozone layer

Not applicable

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Labels

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable

ls : Not applicable



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 402618-00022 Date of first issue: 2015/12/11

Environmentally hazardous : no

IATA-DGR

UN/ID No. : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Packing instruction (cargo : Not applicable

aircraft)

Packing instruction (passen- : Not applicable

ger aircraft)

IMDG-Code

UN number Not applicable Proper shipping name Not applicable Class : Not applicable : Not applicable Subsidiary risk : Not applicable Packing group Labels : Not applicable **EmS Code** Not applicable Marine pollutant Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

Refer to section 15 for specific national regulation.

Special precautions for user

Not applicable

15. REGULATORY INFORMATION

Related Regulations

Fire Service Law

Not applicable to dangerous materials / designated flammables.

Chemical Substance Control Law

Not applicable for Specified Chemical Substance, Monitoring Chemical Substance and Priority Assessment Chemical Substance.

Industrial Safety and Health Law

Harmful Substances Prohibited from Manufacture

Not applicable

Harmful Substances Required Permission for Manufacture

Not applicable

Substances Prevented From Impairment of Health

Not applicable



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 402618-00022 Date of first issue: 2015/12/11

Circular concerning Information on Chemicals having Mutagenicity - Annex 2: Information on Existing Chemicals having Mutagenicity

Not applicable

Circular concerning Information on Chemicals having Mutagenicity - Annex 1: Information on Notified Substances having Mutagenicity

Not applicable

Substances Subject to be Notified Names

Article 57-2 (Enforcement Order Table 9)

Chemical name	Concentration (%)	Remarks
Magnesium stearate	>=1 - <10	-

Substances Subject to be Indicated Names

Article 57 (Enforcement Order Article 18)

Chemical name	Remarks
Magnesium stearate	-

Skin and Eye Damage Substances for PPE Requirements (ISHL MO Art. 594-2)

Not applicable

Carcinogenic Substances (Article 577-2 of the Occupational Health and Safety Regulations)

Not applicable

Ordinance on Prevention of Hazards Due to Specified Chemical Substances

Not applicable

Ordinance on Prevention of Lead Poisoning

Not applicable

Ordinance on Prevention of Tetraalkyl Lead Poisoning

Not applicable

Ordinance on Prevention of Organic Solvent Poisoning

Not applicable

Enforcement Order of the Industrial Safety and Health Law - Attached table 1 (Dangerous Substances)

Not applicable

Poisonous and Deleterious Substances Control Law

Not applicable

Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the Environment and Promotion of Improvements to the Management Thereof

Not applicable

High Pressure Gas Safety Act

Not applicable

Explosive Control Law

Not applicable



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 402618-00022 Date of first issue: 2015/12/11

Vessel Safety Law

Not regulated as a dangerous good

Aviation Law

Not regulated as a dangerous good

Marine Pollution and Sea Disaster Prevention etc Law

Bulk transportation : Not classified as noxious liquid substance

Pack transportation : Not classified as marine pollutant

Narcotics and Psychotropics Control Act

Narcotic or Psychotropic Raw Material (Export / Import Permission)

Not applicable

Specific Narcotic or Psychotropic Raw Material (Export / Import permission)

Not applicable

Waste Disposal and Public Cleansing Law

Industrial waste

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

In this SDS, if the concentration of substances subject to notification under the Industrial Safety and Health Law is indicated as a range, it includes cases where it is a trade secret.

Further information

Sources of key data used to : compile the Safety Data

Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule;



Ribavirin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 402618-00022 Date of first issue: 2015/12/11

ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System: GLP - Good Laboratory Practice: IARC - International Agency for Research on Cancer: IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States): UN - United Nations: UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

JP / EN